title: [The clinical significance of β-arrestin 2 expression in the serum of non-small cell lung cancer patients].
abstract: OBJECTIVE
  Non-small cell lung cancer (NSCLC) with high morbidity and mortality is the most common types of lung cancer. beta-arrestin 2 is a kind of soluble protein regulating signal transduction mediated by G protein coupling receptor. The aim of this research is to evaluate the clinical significance of β-arrestin 2 expression in the serum of NSCLC patients.
  
  
  METHODS
  The clinical and follow-up data of 20 healthy candidates and 67 patients diagnosed with NSCLC in Sun Yat-sen University Cancer Center from January 2005 to December 2006 was retrospectively analyzed. ELISA was applied to detect the expression of beta-arrestin 2.
  
  
  RESULTS
  The serum level of β-arrestin 2 in NSCLC patients were all Significantly lower than those in healthy controls (P<0.001, P<0.001, P<0.001). The serum level of β-arrestin 2 in stage I NSCLC patients were higher than those in stage III as well as in stage IV (P<0.001, P<0.001). No statistical difference of β-arrestin 2' serum level was found between with stage III and stage IV patients (P=0.273). Univariate prognostic factor analyzed by Kaplan-Meier method indicated patients' prognosis with high serum level of β-arrestin 2 was better than patients with low and middle (P<0.001, P<0.001). The serum level of β-arrestin 2 and the stage of NSCLC signally affected prognosis in COX regression model (P=0.003, P=0.004).
  
  
  CONCLUSIONS
  The serum level of β-arrestin 2 had significant difference between NSCLC patients and healthy controls, likewise between the early and advanced NSCLC patients. The serum level of β-arrestin 2 affected NSCLC patients' prognosis.
authors.affiliation: Department of Chest Surgery, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China.
authors.forename: Zhengqing
authors.initials: Z
authors.lastname: Wu
authors.forename: Wenxia
authors.initials: W
authors.lastname: Tong
authors.forename: Zihui
authors.initials: Z
authors.lastname: Tan
authors.forename: Siyu
authors.initials: S
authors.lastname: Wang
authors.forename: Peng
authors.initials: P
authors.lastname: Lin
mesh_terms: D000328:Adult; D000368:Aged; D019390:Arrestins / Q000097:blood* / Q000378:metabolism*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D000071560:beta-Arrestin 2; D000071557:beta-Arrestins
chemical_list: C000605254:ARRB2 protein, human; D019390:Arrestins; D000071560:beta-Arrestin 2; D000071557:beta-Arrestins